SOURCE: Paragon Financial Limited

Paragon Financial Limited

October 29, 2012 08:20 ET

FDA Considering Faster Approval Process for Developers of Drugs for Deadly or Debilitating Diseases

The Paragon Report Provides Stock Research on Novavax and Cardium Therapeutics

NEW YORK, NY--(Marketwire - Oct 29, 2012) - The Food and Drug Administration Commissioner Margaret Hamburg has told scientific advisers that the FDA is considering a faster pathway for obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit. The Paragon Report examines investing opportunities in the Biotech Industry and provides equity research on Novavax, Inc. (NASDAQ: NVAX) and Cardium Therapeutics Inc. (NYSE: CXM).

Access to the full company reports can be found at:
www.ParagonReport.com/NVAX
www.ParagonReport.com/CXM

Under the new pathway the FDA would allow developers of such drugs to conduct smaller, faster clinical trial, and provide a "special medical use" label which would allow doctors to administer drugs to patients with critical need. Hamburg has said that the FDA needs to take into account the needs people with deadly or debilitating diseases that may be willing to take on the risks of unproven drugs.

"A pathway that would allow products to come to market faster but would ensure they were used only in patients where there was an applicable risk-benefit situation would be good," said Pew Health Group's Allan Coukell, deputy director of medical programs. "It would be good for developers, for companies and it would be good for public health."

Paragon Report releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Novavax is a clinical-stage biopharmaceutical company creating recombinant protein nanoparticle vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle and recombinant protein micelle technologies, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections.

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetization. The company recently announced the acquisition of To Go Brands, who reported approximately 1.7 in revenues during the first six months of 2012.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
http://www.paragonreport.com/disclaimer